A method of delivering a therapeutic substance for treatment to a region of the body through vascular isolation and manipulation of fluid flux into and from the region of the body including the steps of: restricting vascular inflow to the region of the body; washing out oncotically active plasma proteins from the region of the body by increasing the outward oncotic pressure gradient from the region of the body; inducing ischemia in the region of the body; controlling the pressure and fluid flow of the main blood vessels to and from the region of the body; providing the therapeutic substance to the region of the body when the fluid flow to the region of the body is controlled.

A cannula for subcutaneous dispensing of medicaments, wherein the cannula has a cannula wall, a distal end and a proximal end and wherein the cannula comprises a single orifice in the cannula wall, proximal to the distal end of the cannula or two or more orifices in the cannula wall, proximal to the distal end of the cannula.

Described herein is an implantable access port device with a catheter compartment which permits lengthening or shortening the catheter in response to changes in tension of the distal catheter. Implantable access port devices are used extensively in the medical field to facilitate the performance of recurrent therapeutic tasks such as repeated drug delivery, drainage, blood sampling, transfusions, or total parental nutrition. In current access port systems, the catheter is rigidly attached to the access port via a connection ring. As such, the system does not provide any flexibility or ability for catheter length adjustments, which can lead to long-term complications such as dislodgement of catheters, migration of catheters, port separation with extravasation, suture disruption, and mechanical failure of the access port system. These catheter-related complications carry serious risks for the patients. The implantable access port system described herein permits self-adjusting catheter length, thereby reducing catheter-related complications.

An implantable cranial medical device includes a first fluid flow path, a second fluid flow path, and upper flange portion, and a lower portion. The upper flange portion is configured to rest on a skull of a subject about a burr hole. The lower portion is configured to be placed within the burr hole. The first fluid flow path may extend from a first opening in the upper flange portion to a first opening in the lower portion. The second fluid flow path may extend from a second opening in the upper flange portion to a second opening in the lower portion.

A multi-use disinfecting cap and method for disinfection and protection of a needleless IV injection port. The disinfecting cap has an upper chamber which contains a sterilizing solution and a low chamber which connects to a needleless IV injection port. The fluid can be manipulated to flow between the two chambers. When in use the cap protects and disinfects a needleless IV injection port when exposed prior to injecting medication into the needleless port and continues to disinfect and protect prior for any subsequent exposures. The cap is re-usable and provides a clear indication of the disinfecting solution and a datable top surface. The multi-use disinfecting cap may be removably clipped to the IV tubing and is shaped to prevent accidental rolling away if dropped.

Disclosed are toggling vascular access port and methods of deploying thereof. The port includes a port body coupled with a septum member covering a cavity defined by the port body, and at least one port body extension restrictedly movable along an at least one defined route on the port body. The port is selectively changeable from a delivery configuration to a deployed configuration by moving the at least one port body extension along the at least one defined route wherein the at least one port body extension and the port body are approximated along a median plane of the port body and laterally opposing portions of the at least one port body extension are parted transversely to the median plane, thereby reducing length-to-width ratio of the toggling vascular access port.

An introducer assembly is adapted for deploying a medical device. The introducer assembly includes an introducer body that is adapted to accommodate a volume of blood therein. An antechamber is coupled with the introducer body. A first hemostasis valve is disposed proximal of the antechamber and fluidly couples the introducer body with the antechamber. A second hemostasis valve is disposed distal of the antechamber and is adapted to allow the medical device to pass therethrough.

A subcutaneous port assembly includes a base, a connector, a stem, a sealing element, and a locking member. The connector extends from a first end attached to the base to a distal end and includes an inner surface defining a socket having an inside diameter. The stem extends from the base and into the socket. The stem includes an outer surface having an outside diameter that is less than the inside diameter of the socket. The sealing element is disposed within the socket between the stem and the inner surface of the socket. The locking member has a plunger received within the socket from the distal end and having a terminal end facing the sealing element. The plunger is axially movable between a first position and a second position to selectively compress the sealing element within the socket.

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

An embodiment includes a vascular port comprising: first and second portions that are not monolithic with each other; wherein: (a)(i) the first portion includes a first arcuate surface to contour to a first portion of a vessel and the second portion includes a second arcuate surface to contour to a second portion of the vessel; (a)(ii) the first and second portions couple to one another around the vessel when implanted to form a central chamber that houses the vessel; (a)(iii) the first portion includes a port that includes a funnel with a funnel surface that narrows as the funnel surface approaches the central chamber; (a)(iv) the central chamber includes a central longitudinal axis and the funnel includes a central vertical axis that is orthogonal to the longitudinal axis; (a)(v) the second portion includes a hardened, non-compliant surface that intersects the vertical axis.